Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands-Reference-Cited by-同舟云学术

Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

Published:2020-01-03 Issue:3 Volume:29 Page:296-305
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Morales Daniel R.¹,Morant Steve V.¹,MacDonald Thomas M.¹^ORCID,Mackenzie Isla S.¹,Doney Alexander S. F.¹,Mitchell Lyn¹,Bennie Marion²,Robertson Chris³,Hallas Jesper⁴^ORCID,Pottegard Anton⁴^ORCID,Ernst Martin Thomsen⁴,Wei Li⁵,Nicholson Lizzie⁶,Morris Carole⁶,Herings Ron M. C.⁷,Overbeek Jetty A.⁷,Smits Elisabeth⁷,Flynn Robert W. V.¹

Affiliation:

1. MEMO ResearchUniversity of Dundee UK

2. Strathclyde Onstitute of Pharmacy and Biomedical SciencesUniversity of Strathclyde Glasgow UK

3. Dept of Mathematics and StatisticsUniversity of Strathclyde Glasgow UK

4. Dept of Clinical Pharmacology and PharmacyUniversity of Southern Denmark Odense Denmark

5. School of PharmacyUniversity College London London UK

6. Electronic Data Research and Innovation ServiceNHS National Services Scotland Edinburgh UK

7. PHARMO Institute for Drug Outcomes Research Utrecht The Netherlands

Funder

European Medicines Agency

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4955

Reference22 articles.

1. Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

2. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population

3. New safety advice for diclofenac—new measures aim to minimise cardiovascular risks.http://www.ema.europa.eu/docs/en_GB/document_libra ry/Referrals_ document/Diclofenac‐containing_medicinal_products/European_Commission_final_decision/WC500155819.pdf (Accessed on May 30 2018)

4. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

5. Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling study;BMJ;2024-07-24

2. Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018–2021: A Qualitative Analysis of Industry‐Sponsored Post‐Authorization Safety Studies;Clinical Pharmacology & Therapeutics;2024-07-12

3. Scoping review of interventions to de-implement potentially harmful non-steroidal anti-inflammatory drugs (NSAIDs) in healthcare settings;BMJ Open;2024-04

4. Spironolactone Induces Vasodilation by Endothelium-Dependent Mechanisms Involving NO and by Endothelium-Independent Mechanisms Blocking Ca2+ Channels;Journal of Xenobiotics;2024-03-01

5. Unintended impact of pharmacovigilance regulatory interventions: A systematic review;British Journal of Clinical Pharmacology;2023-08-28